We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare.
- Authors
Kuehn, Bridget M.
- Abstract
News From the Centers for Disease Control and Prevention Hospitalizations and emergency department visits for rebounding COVID-19 symptoms are rare after treatment with the antiviral therapy nirmatrelvir-ritonavir, according to a CDC analysis of electronic medical records from a large health care system. Case reports of rebounding COVID-19 symptoms or positive SARS-CoV-2 test results between 2 and 8 days after treatment with the antiviral therapy prompted the CDC to issue a Health Advisory on May 24. Less than 1% of 5287 patients who received nirmatrelvir-ritonavir for COVID-19 required hospitalization or emergency department care for symptoms 5 to 15 days after treatment, according to the CDC report.
- Subjects
HOSPITAL emergency services; COMBINATION drug therapy; ANTIVIRAL agents; ORGANIC compounds; PATIENT readmissions; PROLINE; LEUCINE; RITONAVIR; HOSPITAL care; AMIDES
- Publication
JAMA: Journal of the American Medical Association, 2022, Vol 328, Issue 4, p323
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2022.11942